πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116346

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116343

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12115156

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12103907

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Arcus Biosciences, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097210

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097262

mTORC1 inhibitors

The Regents of the University of California Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083141

Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083098

Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form Ξ² inhibito

ACTUATE THERAPEUTICS INC. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12084438

GCN2 inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12084447

SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083137

Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083113

Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

Northwestern University Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12076324

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12077515

Selective histone deacetylase inhibitors for the treatment of human disease

Shuttle Pharmaceuticals, Inc. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12077605

Cysteine protease inhibitors and methods of use thereof

Anixa Biosciences, Inc. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12077506

Indane derivatives as hypoxia inducible factor-2(Ξ±) inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12071411

Inhibitors of HIF-2Ξ± and methods of use thereof

Arcus Biosciences, Inc. Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12070460

Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12071428

Indazole compounds as kinase inhibitors

TYRA BIOSCIENCES, INC. Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12065448

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12060396

Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis

THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12060362

Inhibitors of glucose transporters (GLUTs)

Lead Discovery Center GmbH Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted